CompanyGraph
Use to find companies where this pattern is active.
R&D expense is a large share of revenue; diluted share count has grown on a 6-year basis; stock-based compensation is a large share of trailing revenue.
State
High R&D-to-revenue co-occurs with positive 6-year share-count CAGR and elevated SBC-to-revenue
Emergence
Three ratios line up: R&D expense is a large share of annual revenue, diluted shares outstanding have a positive 6-year CAGR (scaled against 10% per year), and stock-based compensation is a large share of TTM revenue (scaled against 8%). The three readings describe expense composition and share-count trajectory in the same window; they do not establish a causal funding link between SBC and R&D.
Limits
Each observation records an accounting ratio or share-count trajectory. None measures whether R&D produces innovation, whether the dilution returned more value per share than it cost, or whether SBC is the funding source for R&D. The share-count CAGR clips negative values to zero, so the score reflects growth only — buyback periods within the 6-year window can offset issuance but not produce a negative reading. Industry norms for SBC-to-revenue vary widely (high in software/tech, low in industrials); the score is not industry-benchmarked here.
Explanation
Three readings co-occur: - R&D Intensity: R&D expense as a fraction of annual revenue (mapped on a 0–30% scale). - Diluted Share Count Growing (share-dilution-ratio): 6-year CAGR of diluted shares outstanding, clipped at zero (a 10% CAGR maps to score 100). A near-duplicate (shares-outstanding-trend) uses an 8-year window and centered mapping. - Stock-Based Compensation Relative to Revenue: annualized SBC as a fraction of TTM revenue (mapped on a 0–8% scale). The three describe expense composition (R&D, SBC) and a share-count trajectory. The formulas do not say whether the dilution is a funding source for the R&D, whether the R&D is producing returns, or what industry-normal SBC levels are.
Interpretation
Co-occurrence of high R&D-to-revenue, multi-year diluted-share-count growth, and elevated SBC-to-revenue. The formulas record ratios and a CAGR; they do not establish a causal funding link between SBC and R&D or assess value creation.
Required Observations
Rd Intensity
R&D expense as a share of revenue
Sbc Share Of Revenue
Stock-based compensation expense as a share of trailing twelve-month revenue.
Share Dilution Ratio
Diluted shares outstanding have grown on a 6-year compound basis.